Insider Transactions in Q4 2023 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,000
-0.32%
|
$336,000
$28.54 P/Share
|
|
Dec 15
2023
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+18.55%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+11.55%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+10.15%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Victoria Vakiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+28.98%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+39.61%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+22.44%
|
$374,675
$25.41 P/Share
|
|
Nov 20
2023
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,700
-6.68%
|
$551,600
$28.87 P/Share
|
|
Oct 25
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,338
-0.65%
|
$584,112
$24.21 P/Share
|